-transparent.png){kind=logo}
Buprenorphine (0.3-3.0 mg/kg) produced dose-dependent protection against the lethal effects of cocaine in mice. The (+)-enantiomer of buprenorphine did not protect up to doses over 100 times greater than the lowest effective dose of its (-)-enantiomer. The protective effects were also produced by the opioid agonists morphine and methadone, but not by the opioid antagonist, naltrexone. Low doses of naltrexone (0.3-1.0 mg/kg) blocked the protective effects of buprenorphine. Protection conferred by buprenorphine was not observed in CXBK mice, a recombinant inbred strain relatively devoid of mu-opioid receptors. Thus, buprenorphine appears to protect against the lethal effects of cocaine by a process mediated by mu-opioid receptors. The present results should provide some additional safety assurance in future clinical trials with buprenorphine, especially in outpatient trials where cocaine abuse may continue along with treatment.
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
April 1983,
British journal of pharmacology,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
February 2015,
Psychoneuroendocrinology,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
June 2009,
The Journal of neuroscience : the official journal of the Society for Neuroscience,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
January 1993,
Biological psychiatry,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
April 2022,
Journal of medical case reports,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
January 2019,
European addiction research,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
December 1993,
The American journal of physiology,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
December 2022,
Progress in neuro-psychopharmacology & biological psychiatry,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
July 1995,
The Journal of pharmacology and experimental therapeutics,
J M Witkin, and
R E Johnson, and
J H Jaffe, and
S R Goldberg, and
N A Grayson, and
K C Rice, and
J L Katz
July 2006,
The Journal of pharmacology and experimental therapeutics,
